TRAIL Receptor Targeting Agents Potentiate PARP Inhibitor Efficacy in Pancreatic Cancer Independently of BRCA2 Mutation Status.
Ben Khaled N, Hammer K, Ye L, Alnatsha A, Widholz SA, Piseddu I, Sirtl S, Schneider J, Munker S, Mahajan UM, Montero JJ, Griger J, Mayerle J, Reiter FP, De Toni EN.
Ben Khaled N, et al. Among authors: sirtl s.
Cancers (Basel). 2022 Oct 26;14(21):5240. doi: 10.3390/cancers14215240.
Cancers (Basel). 2022.
PMID: 36358659
Free PMC article.